Clade Therapeutics is developing novel induced pluripotent stem cell (iPSC)-based therapies that can avoid immunogenic reactions. iPSCs are a type of stem cell that derive from mature cells and have the ability to proliferate and differentiate into different cell types - they therefore have much potential for regenerative medicine. However, for mass adoption, these iPSCs need to be suitable for all patients and not trigger the patient's immune response. To create these so-called “off-the-shelf” therapies, Clade is using their proprietary technology platform to “cloak” the immune system of iPSCs. Initially, Clade is exploring this technology to employ iPSCs in cancer therapies.

Clade Therapeutics

Founded: 2020
Location: Cambridge, MA
Employee range: 11 - 50
Funding: $87M A Nov 2021

Short description:

Drug notes:

Long description:

Jobs: